Preclinical Evaluation of a Novel Tris Amine Derivative in Animal Models of Anxiety and Depression

Abstract

Anxiety and depression are among the most prevalent mental health disorders, affecting a vast portion of the population. Despite the well-established efficacy of first-line anxiolytic and antidepressant treatments, their significant side effects often drive individuals to seek alternative therapies. Trisamine-based drugs have drawn interest in the modern age because of their potency, efficacy, broad pharmacological activity, and decreased adverse effects. They are a safer, more effective, and more affordable option for treating mental health issues because of their promising therapeutic profile. Trisamine derivatives' neuropharmacological potential was assessed in this study, with a focus on their sedative, anxiolytic, and antidepressant properties. The chosen compound was screened using a variety of behavioral models, and the results were significant. Compound M-1 showed sedative activity in open field test, similarly it demonstrated highly significant (***P< 0.001) anxiolytic effects in behavioral assessments. Although compound M-1 proved to be effective at high doses in forced swimming test (FST), the activity become decreased with dose which shows it has dose dependant antidepressant activity.The selected compounds exhibited strong neuropharmacological effects.